title: [Ablation of atrial fibrillation: where are we now?].
abstract: Atrial fibrillation is the commonest arrhythmia. Besides the risk of complications, a significant number of patients remain symptomatic despite the different anti-arrhythmic drugs currently available. The only curative treatment is by surgery or catheter ablation. Since 1994, several approaches have been developed based on two main concepts: modification of the arrhythmogenic substrate by linear lesion to prevent the perpetuation of the arrhythmia and ablation of the foci initiating the atrial fibrillation. The later approach is the most popular one at the moment because the concentration of foci at the site of the pulmonary veins makes it possible to isolate them relatively easily. The presence of atrial foci in some patients complicates matters and limits the success rate to 70%. Despite these limitations and with an acceptable rate of complications, this approach appears preferable to His bundle ablation in young patients with symptomatic paroxysmal atrial fibrillation resistant to antiarrhythmic therapy.
authors.affiliation: Hôpital cardiologique du Haut-Léveque, avenue de Magellan, 33604 Pessac.
authors.forename: P
authors.initials: P
authors.lastname: Jaïs
authors.forename: M
authors.initials: M
authors.lastname: Haïssaguerre
authors.forename: J
authors.initials: J
authors.lastname: Clémenty
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D004351:Drug Resistance; D006801:Humans; D008875:Middle Aged; D018579:Patient Selection; D011183:Postoperative Complications; D012307:Risk Factors
chemical_list: D000889:Anti-Arrhythmia Agents